Therapeutics(LENZ)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

LENZ Therapeutics

交易中 06-16 15:45:17 EDT

6.58

-0.05

-0.83%

最高6.70	最低6.45	成交量15.76万
今开6.59	昨收6.63	日振幅3.77%
总市值2.06亿	流通市值1.03亿	总股本3,129万
成交额103.38万	换手率1.00%	流通股本1,569万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"LENZ","market":"US","secType":"STK","nameCN":"Therapeutics","latestPrice":6.575,"timestamp":1781639117057,"preClose":6.63,"halted":0,"volume":157625,"delay":0,"changeRate":-0.008295625942684723,"floatShares":15692500,"shares":31289969,"eps":-3.661292,"marketStatus":"交易中","change":-0.055,"latestTime":"06-16 15:45:17 EDT","open":6.59,"high":6.7,"low":6.45,"amount":1033845.5091250001,"amplitude":0.037707,"askPrice":6.59,"askSize":312,"bidPrice":6.58,"bidSize":309,"shortable":3,"etf":0,"ttmEps":-3.661292,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1781640000000},"marketStatusCode":2,"adr":0,"listingDate":1624593600000,"exchange":"NASDAQ","adjPreClose":6.63,"preHourTrading":{"tag":"盘前","latestPrice":6.65,"preClose":6.63,"latestTime":"08:56 EDT","volume":1870,"amount":12114.61174,"timestamp":1781614574685,"change":0.02,"changeRate":0.003017,"amplitude":0.075415},"postHourTrading":{"tag":"盘后","latestPrice":6.89,"preClose":6.63,"latestTime":"19:45 EDT","volume":89119,"amount":591242.365,"timestamp":1781567119313,"change":0.26,"changeRate":0.039216,"amplitude":0.044495},"volumeRatio":0.335448,"impliedVol":5.3604,"impliedVolPercentile":0.996},"requestUrl":"/m/hq/s/LENZ","defaultTab":"news","newsList":[{"id":"2642382782","title":"Viking Therapeutics任命Hubert C. Chen博士为新任首席医疗官","url":"https://stock-news.laohu8.com/highlight/detail?id=2642382782","media":"环球市场播报","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642382782?lang=zh_cn&edition=full","pubTime":"2026-06-11 23:06","pubTimestamp":1781190360,"startTime":"0","endTime":"0","summary":"临床阶段生物制药公司Viking Therapeutics周四宣布，任命Hubert C． Chen博士为首席医疗官。Chen博士将负责领导公司的临床开发、医学及监管事务，直接向公司总裁兼首席执行官Brian Lian博士汇报。在加入Viking之前，他曾担任Loyal Animal Health的首席研发官，领导了首个与美国食品药品监督管理局达成谈判的长寿疗法有效性和安全性要求制定工作。　　这一任命正值Viking推进其核心候选药物VK2735的关键时期。Viking还计划于本季度启动新型胰淀素激动剂VK3019的一期临床试验。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-06-11/doc-inicaenm0642884.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4139","159891","BK4539","LENZ","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169652203","title":"Lenz宣布与云顶新耀达成协议，后者获Vizz®(Lnz100)大中华区开发及商业化权益","url":"https://stock-news.laohu8.com/highlight/detail?id=1169652203","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1169652203?lang=zh_cn&edition=full","pubTime":"2026-06-08 07:31","pubTimestamp":1780875098,"startTime":"0","endTime":"0","summary":"Lenz Therapeutics公司宣布，已与Everest Medicines（云顶新耀）达成授权协议。根据协议，云顶新耀获得了在大中华区（包括中国大陆、香港、澳门及台湾）开发和商业化Vizz®（研发代号Lnz100）的独家权利。\n该交易标志着Lenz的核心产品管线进入了重要的亚太市场。Vizz®（Lnz100）是一款处于研发阶段的创新疗法，此次合作将加速该产品在广阔的大中华区的临床开发与未来市场准入。\n通过此次授权，Lenz有望获得包括首付款、里程碑付款以及基于未来销售额的特许权使用费在内的潜在收益。云顶新耀则将凭借其在本地区的开发与商业化能力，推动该产品的上市进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LENZ","BK4539","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640594153","title":"Kazia Therapeutics任命资深交易专家James Levine为新任CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2640594153","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640594153?lang=zh_cn&edition=full","pubTime":"2026-06-02 22:48","pubTimestamp":1780411680,"startTime":"0","endTime":"0","summary":"澳大利亚临床阶段肿瘤公司Kazia Therapeutics Limited宣布，任命James Levine为首席财务官，自2026年6月1日起生效。Levine拥有超过二十年的投资银行及生物技术公司高管经验，曾在高盛担任董事总经理，并领导过总计数十亿美元的生物医药交易。　　Levine近期担任Cardiff Oncology首席财务官，此前曾任Cidara Therapeutics首席财务官，主导了与Mundipharma及强生旗下Janssen Pharmaceuticals的财务架构设计。　　Kazia的核心资产paxalisib是一款口服、可入脑的PI3K/mTOR双重抑制剂，正在开发用于多种癌症。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-06-02/doc-inhzzumh2971166.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4539","LENZ","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640492479","title":"Vector Science & Therapeutics授出20.6万份期权 持续推进增长战略","url":"https://stock-news.laohu8.com/highlight/detail?id=2640492479","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640492479?lang=zh_cn&edition=full","pubTime":"2026-06-02 22:39","pubTimestamp":1780411140,"startTime":"0","endTime":"0","summary":"Vector Science & Therapeutics Corp．周二宣布，公司董事会已批准向部分董事授予206，610份股票期权，行权价为每股1.69加元。此举正值公司近期完成多项战略布局、加速推进增长战略之际。此次期权授予尚需获得多伦多证券交易所创业板的批准。　　公司于今年4月完成在多伦多证券交易所创业板的上市，股票代码PAIN，为这一增长战略的推进提供了资本市场支持。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-06-02/doc-inhzzumk4647843.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4139","BK4007","BK4561","VAQC","LENZ","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640954794","title":"Seaport Therapeutics将出席两大投资者会议，聚焦神经精神药物研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2640954794","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640954794?lang=zh_cn&edition=full","pubTime":"2026-06-01 21:09","pubTimestamp":1780319340,"startTime":"0","endTime":"0","summary":"Seaport Therapeutics是一家专注于开发新型神经精神疾病疗法的临床阶段生物制药公司，近日宣布其管理团队将参与两场即将举行的投资者会议。　　根据公司发布的消息，Seaport将出席高盛第47届年度全球医疗保健会议，炉边谈话定于2026年6月10日上午8点举行。　　Seaport Therapeutics总部位于马萨诸塞州波士顿，于2024年成立，2026年5月1日在纳斯达克完成IPO上市，股票代码为SPTX。此次参与两大投资者会议，Seaport将向投资界分享其在神经精神药物研发领域的最新进展与战略规划。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-06-01/doc-inhzxmef5038397.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4139","BK4539","LENZ","BK4007","SPTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639725276","title":"BMS多发性骨髓瘤III期数据亮眼 C4 Therapeutics受提振大涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2639725276","media":"环球市场播报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639725276?lang=zh_cn&edition=full","pubTime":"2026-05-30 03:49","pubTimestamp":1780084140,"startTime":"0","endTime":"0","summary":"百时美施贵宝日前公布了其在研药物美齐格米德的III期临床试验阳性数据。结果显示，该联合疗法将复发或难治性多发性骨髓瘤患者的疾病进展或死亡风险降低了52%。这一积极结果不仅推高了施贵宝的股价，也显著提振了同领域生物科技公司C4 Therapeutics的市场表现。　　在施贵宝宣布这一消息后，C4 Therapeutics股价应声大涨，盘中一度触及52周新高，最终收涨逾19%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-05-30/doc-inhzrera0552232.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4539","BK4139","LENZ","CCCC","BMS","BK4007","BK4134","III"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639675738","title":"Aldeyra Therapeutics投资者迎来集体诉讼主导权申请截止日","url":"https://stock-news.laohu8.com/highlight/detail?id=2639675738","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639675738?lang=zh_cn&edition=full","pubTime":"2026-05-29 22:54","pubTimestamp":1780066440,"startTime":"0","endTime":"0","summary":"生物制药公司Aldeyra Therapeutics近日面临证券欺诈集体诉讼，多家律所提醒投资者，申请担任首席原告的截止日期为2026年5月29日。　　此次诉讼源于美国食品药品监督管理局于2026年3月17日对该公司的干眼症候选药物reproxalap新药申请发出完全回复函，正式拒绝批准。　　诉讼指控在2023年11月3日至2026年3月16日期间，Aldeyra及其部分高管违反了联邦证券法，就reproxalap临床试验结果作出了虚假和误导性陈述，未能披露试验数据的不一致性。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-05-29/doc-inhzqtze7774976.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4539","BK4139","LENZ","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638684358","title":"Turn Therapeutics发表GX-03抗炎新数据，助力皮肤病精准治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=2638684358","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638684358?lang=zh_cn&edition=full","pubTime":"2026-05-27 23:35","pubTimestamp":1779896100,"startTime":"0","endTime":"0","summary":"Turn Therapeutics近日宣布，一篇关于其先导候选药物GX-03在IL-36相关炎症模型中活性的同行评审研究论文，已发表于《皮肤病学治疗杂志》。该研究为GX-03治疗中重度特应性皮炎的作用机制提供了新的科学依据，标志着公司对炎症性皮肤病局部治疗研究方法的转变。就在上月，Turn Therapeutics还与Avenue Capital Group旗下基金达成了一项最高2500万美元的成长资本贷款协议，首笔700万美元已到账，将用于支持GX-03项目的推进并可能将现金跑道延续至2期数据公布之后。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-05-27/doc-inhzkfvc1468955.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LENZ","BK4139","BK4007","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638896436","title":"临床阶段RNAi疗法公司Silence Therapeutics将出席Jefferies全球医疗保健年会","url":"https://stock-news.laohu8.com/highlight/detail?id=2638896436","media":"环球市场播报","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638896436?lang=zh_cn&edition=full","pubTime":"2026-05-27 22:37","pubTimestamp":1779892620,"startTime":"0","endTime":"0","summary":"临床阶段RNAi疗法公司Silence Therapeutics近日宣布，公司管理层将出席2026年6月3日下午4：55举行的Jefferies全球医疗保健年会，并进行分析师主导的炉边谈话。投资者可通过公司官网投资者关系页面收听现场网络直播，回放将在会议结束后提供。　　Silence Therapeutics目前最受关注的资产是divesiran，一种靶向TMPRSS6的siRNA疗法，用于治疗真性红细胞增多症。　　Silence Therapeutics总部位于伦敦，在纳斯达克以“SLN”代码交易，员工约88人。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-05-27/doc-inhzkfvc1451718.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4581","BK4007","BK4585","BK4539","VHT","LENZ","XLV","BK4139","XBI","BK4550","BK4588","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635035245","title":"Indaptus Therapeutics Q1净亏损收窄，现金储备大幅下降","url":"https://stock-news.laohu8.com/highlight/detail?id=2635035245","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635035245?lang=zh_cn&edition=full","pubTime":"2026-05-15 23:46","pubTimestamp":1778859960,"startTime":"0","endTime":"0","summary":"　　Indaptus Therapeutics公布2026年第一季度财报。公司报告期内净亏损为254万美元，合每股亏损0.23美元，较上年同期的453万美元亏损和每股亏损9.11美元显著收窄。每股亏损的大幅减少主要源于2025年6月实施的1比28反向股票分割带来的股份数量增加。一般及行政费用为167万美元，同比略有下降。　　截至季末，公司现金及现金等价物仅为150万美元，较2025年末的850万美元大幅下降。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-05-15/doc-inhxyyie6357238.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LENZ","BK4007","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635035758","title":"Atrium Therapeutics Q1净亏损1660万美元，BMS里程碑付款支撑收入","url":"https://stock-news.laohu8.com/highlight/detail?id=2635035758","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635035758?lang=zh_cn&edition=full","pubTime":"2026-05-15 23:41","pubTimestamp":1778859660,"startTime":"0","endTime":"0","summary":"　　Atrium Therapeutics公布2026年第一季度财报。公司报告期内净亏损为1663万美元，合每股亏损0.97美元。作为对比，公司在作为Avidity Biosciences子公司期间的2025年同期净亏损为745万美元，合每股亏损0.44美元。需要说明的是，由于Atrium于2026年2月27日才完成从Avidity的分拆独立上市，本期财务数据不宜直接与历史同期进行比较。　　Atrium于2月27日正式作为独立公司登陆纳斯达克。ATR 1072的IND申请预计于2026年下半年提交，ATR 1086的IND申请预计于2027年提交。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-05-15/doc-inhxyyie6355365.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["RNA","BK4539","BK4007","BK4505","LENZ","BK4588","IE0009354923.USD","BK4139","BMS","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635359547","title":"Aptevo Therapeutics公布一季度业绩及临床进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2635359547","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635359547?lang=zh_cn&edition=full","pubTime":"2026-05-13 22:49","pubTimestamp":1778683740,"startTime":"0","endTime":"0","summary":"临床阶段生物技术公司Aptevo Therapeutics周三发布2026年第一季度业务更新，披露现金储备及核心管线试验的最新进展。公司同步宣布完成管理层交接。　　截至2026年3月31日，Aptevo持有现金及现金等价物1450万美元。　　公司同步宣布完成管理层过渡，新任命的首席执行官表示，核心药物持续产生令人信服的一线数据，将强效缓解活性与差异化的安全性特征相结合，有潜力成为标准疗法的重要补充。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-05-13/doc-inhxunaz7338741.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4007","BK4139","LENZ","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109919604","title":"Piper Sandler下调Lenz Therapeutics评级至中性，目标价大幅削减至12美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1109919604","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1109919604?lang=zh_cn&edition=full","pubTime":"2026-05-12 10:34","pubTimestamp":1778553253,"startTime":"0","endTime":"0","summary":"投资银行Piper Sandler宣布，将生物技术公司Lenz Therapeutics的股票评级从“增持”下调至“中性”。与此同时，该机构大幅调降了对该公司的目标股价，从此前的39美元大幅削减至12美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BK4007","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634465519","title":"美股异动 | Odyssey Therapeutics(ODTX.US)登陆美股市场 开盘股价波动不大","url":"https://stock-news.laohu8.com/highlight/detail?id=2634465519","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634465519?lang=zh_cn&edition=full","pubTime":"2026-05-09 00:00","pubTimestamp":1778256000,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，周五，Odyssey Therapeutics(ODTX.US)登陆美股市场，开盘股价波动不大，IPO价格为18美元。截至发稿，该股跌超1%，报17.81美元。Odyssey Therapeutics是一家总部位于美国波士顿的临床阶段生物科技公司，主要专注于自身免疫性及炎症性疾病药物研发。公司核心产品为OD-001，这是一款用于治疗溃疡性结肠炎的小分子药物，目前已进入中期临床试验阶段。此外，公司还布局红斑狼疮、特应性皮炎等多个免疫疾病管线。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1439831.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4139","BK4007","ODTX","BK4539","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633450362","title":"Atossa Therapeutics一季度GAAP每股亏损1.11美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2633450362","media":"环球市场播报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633450362?lang=zh_cn&edition=full","pubTime":"2026-05-08 22:49","pubTimestamp":1778251740,"startTime":"0","endTime":"0","summary":"临床阶段生物制药公司Atossa Therapeutics公布2026年第一季度财报，GAAP每股亏损1.11美元。由于公司尚无商业化产品，本季度未录得营收。　　财报显示，公司一季度净亏损约1.38亿美元，较上年同期净亏损650万美元大幅扩大。剔除一次性项目后，调整后每股亏损约为0.18美元。截至3月31日，公司持有现金及短期投资约1.15亿美元，较年初减少约2000万美元。　　财报发布后，Atossa股价在盘后交易中下跌约5%。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-05-08/doc-inhxfamz4272189.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["UDN","UUP","LENZ","BK4139","BK4007","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633902722","title":"拜耳斥资24.5亿美元收购Perfuse Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2633902722","media":"环球市场播报","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633902722?lang=zh_cn&edition=full","pubTime":"2026-05-06 16:02","pubTimestamp":1778054520,"startTime":"0","endTime":"0","summary":"德国拜耳公司周三宣布，将收购生物制药公司Perfuse Therapeutics，以完善其眼科产品线。\n　　拜耳在一份声明中表示，该交易潜在价值高达24.5亿美元，其中包括3亿美元的首付款，以及根据研发、监管和商业里程碑进展情况支付的额外款项。\n　　该交易将使拜耳获得PER-001的全部权益。PER-001是一种小分子内皮素受体拮抗剂（ERA），目前正处于II期临床开发阶段，用于治疗青光眼和糖尿病视网膜病变。\n　　拜耳表示，此次收购将在获得必要的反垄断审批和Perfuse股东批准后生效。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：于健 SF069","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-05-06/doc-inhwxxki3422808.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LENZ","BK4007","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632511159","title":"亿腾嘉和(06998)：Candid Therapeutics被UCB收购 首付款20亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2632511159","media":"智通财经","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632511159?lang=zh_cn&edition=full","pubTime":"2026-05-04 22:51","pubTimestamp":1777906296,"startTime":"0","endTime":"0","summary":"于2024年9月，Candid Therapeutics, Inc.与TRC 2004, Inc.合并。集团与Candid Therapeutics订立了日期为2025年3月28日的修订协议，以修订及补充许可协议的若干条款，共同推动GB261在自身免疫领域的临床开发。于2026年5月3日，于布鲁塞尔泛欧交易所上市的比利时医药集团Union Chimique Belge宣布已签署一项最终协议，据此其将收购 Candid Therapeutics。根据协议条款，UCB须支付首付款20亿美元，连同高达2亿美元的潜在未来里程碑付款，惟须视乎是否达成指定里程碑而定。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1437957.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4539","BK4007","LENZ","BK1574","BK4211","BK1583","BK1161","06998","BK4139","UCB"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1107930113","title":"LENZ Therapeutics将于2026年5月11日公布第一季度财报并参与投资者会议","url":"https://stock-news.laohu8.com/highlight/detail?id=1107930113","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1107930113?lang=zh_cn&edition=full","pubTime":"2026-05-04 20:02","pubTimestamp":1777896178,"startTime":"0","endTime":"0","summary":"圣地亚哥，2026年5月4日——专注商业化VIZZ1.44%的制药企业LENZ Therapeutics宣布，将于2026年5月11日东部时间下午4:30举行网络直播，披露2026年第一季度财务业绩及近期公司动态。该产品是全球首个且唯一获FDA批准的醋克利定滴眼液，用于治疗成人老花眼。直播链接亦可在LENZ Therapeutics官网的\"投资者与媒体\"专区获取。此外，公司管理层将于2026年5月13日至14日出席在拉斯维加斯举行的美国银行全球医疗健康大会，并安排一对一会议。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4232","BK4007","BK4139","R","LENZ","BK4022","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136316695","title":"Avalo Therapeutics达成里程碑付款买断协议 优化资本结构","url":"https://stock-news.laohu8.com/highlight/detail?id=1136316695","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1136316695?lang=zh_cn&edition=full","pubTime":"2026-04-28 19:15","pubTimestamp":1777374917,"startTime":"0","endTime":"0","summary":"临床阶段生物技术公司Avalo Therapeutics Inc  近日宣布，就2024年3月收购AlmataBio公司所涉条款达成里程碑付款买断协议。通过该选择权，Avalo可选择以现金、普通股或组合形式支付512.5万美元，替代原定在III期临床试验首例患者给药时需支付的1500万美元或有里程碑款项。通过前置部分付款义务，Avalo在保留研发推进主动权的同时，有效规避了未来可能产生的高额里程碑付款风险。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","LENZ","BK4139","BK4007","AVTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629852486","title":"美国FDA拒绝批准Grace Therapeutics脑卒中药物","url":"https://stock-news.laohu8.com/highlight/detail?id=2629852486","media":"环球市场播报","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629852486?lang=zh_cn&edition=full","pubTime":"2026-04-24 02:43","pubTimestamp":1776969780,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局近日已向Grace Therapeutics发出完整回应函，拒绝批准其候选药物治疗特定类型脑卒中（中风）的上市申请。FDA在函件中指出，根据现有数据，暂无法确认该药物的临床获益大于风险，并要求公司在药品获批前补充相关的临床试验数据或生产质量控制信息。　　Grace Therapeutics方面随即回应称，正对FDA的反馈进行详细评估。　　此次拒绝为该公司的新药上市之路增加了新的不确定性，至于Grace是选择提起上诉还是重新提交申请，还有待公司进一步披露。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-04-24/doc-inhvpqks5066320.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LABU","BK4585","LENZ","BK4139","BK4588","BK4539","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://ir.lenz-tx.com","stockEarnings":[{"period":"1week","weight":-0.0134},{"period":"1month","weight":-0.0967},{"period":"3month","weight":-0.4696},{"period":"6month","weight":-0.595},{"period":"1year","weight":-0.7714},{"period":"ytd","weight":-0.5856}],"compareEarnings":[{"period":"1week","weight":0.0211},{"period":"1month","weight":0.0212},{"period":"3month","weight":0.1253},{"period":"6month","weight":0.1243},{"period":"1year","weight":0.2644},{"period":"ytd","weight":0.1069}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"LENZ Therapeutics, Inc.最初于2017年6月1日在加拿大安大略省注册成立，随后于2019年10月在特拉华州重新注册成立。该公司是一家商业制药公司，专注于开发和商业化改善视力的疗法，其主导产品VIZZ被批准用于治疗老花眼。","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":-0.137955},{"month":2,"riseRate":0.4,"avgChangeRate":0.032476},{"month":3,"riseRate":0.2,"avgChangeRate":-0.143415},{"month":4,"riseRate":0.4,"avgChangeRate":-0.0217},{"month":5,"riseRate":0.2,"avgChangeRate":-0.134259},{"month":6,"riseRate":0.6,"avgChangeRate":0.014493},{"month":7,"riseRate":0.6,"avgChangeRate":0.05308},{"month":8,"riseRate":0.4,"avgChangeRate":0.016536},{"month":9,"riseRate":0.6,"avgChangeRate":0.026875},{"month":10,"riseRate":0.6,"avgChangeRate":-0.067546},{"month":11,"riseRate":0.6,"avgChangeRate":-0.005451},{"month":12,"riseRate":0.4,"avgChangeRate":-0.038411}],"exchange":"NASDAQ","name":"Therapeutics","nameEN":"Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Therapeutics(LENZ)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Therapeutics(LENZ)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Therapeutics,LENZ,Therapeutics股票,Therapeutics股票老虎,Therapeutics股票老虎国际,Therapeutics行情,Therapeutics股票行情,Therapeutics股价,Therapeutics股市,Therapeutics股票价格,Therapeutics股票交易,Therapeutics股票购买,Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Therapeutics(LENZ)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Therapeutics(LENZ)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}